Could be, and hope so. Just wondering why NP says running a bigger trial then. I figured 62 subjects may not be big enough for FDA. With our safety profile though, why not?

I think we can guess why overall mortality just 22% in our trial .. most of them were severe not critical (just 15%), and so less of them died.

Would love to hear more about how the discussions are going.